KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)Depreciation ExpenseEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares OutstandingShares Outstanding
Ratios

AbCellera Biologics (ABCL) Leases (2021 - 2026)

AbCellera Biologics filings provide 6 years of Leases readings, the most recent being $134.3 million for Q1 2026.

  • Quarterly Leases rose 95.39% to $134.3 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $134.3 million through Mar 2026, up 95.39% year-over-year, with the annual reading at $136.1 million for FY2025, 104.23% up from the prior year.
  • Leases hit $134.3 million in Q1 2026 for AbCellera Biologics, down from $136.1 million in the prior quarter.
  • Across five years, Leases topped out at $137.9 million in Q3 2025 and bottomed at $6.6 million in Q1 2022.
  • Average Leases over 5 years is $76.5 million, with a median of $72.5 million recorded in 2023.
  • The largest annual shift saw Leases skyrocketed 632.47% in 2023 before it dropped 26.17% in 2025.
  • AbCellera Biologics' Leases stood at $80.8 million in 2022, then dropped by 9.52% to $73.1 million in 2023, then dropped by 8.88% to $66.6 million in 2024, then soared by 104.23% to $136.1 million in 2025, then decreased by 1.33% to $134.3 million in 2026.
  • Per Business Quant, the three most recent readings for ABCL's Leases are $134.3 million (Q1 2026), $136.1 million (Q4 2025), and $137.9 million (Q3 2025).